首页 > 最新文献

Melanoma Research最新文献

英文 中文
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio. 利用黑色素瘤死亡率-发病率比值分析皮肤科医生密度与黑色素瘤预后之间的关系。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-30 DOI: 10.1097/CMR.0000000000001004
Joshua Burshtein, Milaan Shah, Danny Zakria, Darrell Rigel
{"title":"The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio.","authors":"Joshua Burshtein, Milaan Shah, Danny Zakria, Darrell Rigel","doi":"10.1097/CMR.0000000000001004","DOIUrl":"https://doi.org/10.1097/CMR.0000000000001004","url":null,"abstract":"","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"34 6","pages":"550-552"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients. 对儿科非典型和恶性黑色素细胞肿瘤进行部分刮片活检后的治疗效果。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-05 DOI: 10.1097/CMR.0000000000001002
Akshaya Arjunan, Mary Wardrop, Marcus M Malek, Alexander J Davit, Michael R Sargen, John M Kirkwood, Kathryn Demanelis, Brittani K N Seynnaeve

Pediatric melanoma is the most common skin cancer in children and treatment relies on accurate staging. The American Academy of Dermatology recommends excisional biopsy for suspicious skin lesions, however, partial shave biopsies are often performed, the impact of which is unknown in pediatric and adolescent/young adult (AYA) patients. The aim of this retrospective case series study was to evaluate the impact of the diagnostic biopsy method on staging, treatment, and treatment-related outcomes in pediatric/AYA patients with melanoma. Among 103 pediatric/AYA patients with atypical cutaneous melanocytic lesions, the most common biopsy method was partial shave (68/103, 66.0%) followed by punch (20/103, 19.4%), excisional (14/103, 13.6%), and incisional nonshave (1/103, 1%). Over half of all biopsies yielded a positive deep margin, reflecting compromised microstaging (56/103, 55.4%), the majority occurred following partial shave (52/56, 92.9%) compared with other techniques ( P  < 0.001). All 11 patients with wider surgical target margins of wide local excision and 8/9 patients with sentinel lymph node biopsy performed due to positive deep margin, underwent a partial shave biopsy ( P  = 0.05 and 0.32, respectively). Almost half of all patients who underwent partial shave biopsy had a clinically suspected abnormal melanocytic tumor prior to biopsy (31/68, 45.6%; P  = 0.03). Of 56 patients who had compromised microstaging, 17 (30.4%) had a diagnosis of melanoma ( P  = 0.17). Pediatric/AYA patients frequently undergo partial shave biopsy, which is associated with more invasive definitive surgical treatment due to compromised microstaging. These results may help optimize care of patients with cutaneous melanocytic tumors.

小儿黑色素瘤是儿童中最常见的皮肤癌,治疗有赖于准确的分期。美国皮肤病学会建议对可疑皮损进行切除活检,但部分刮片活检经常被采用,其对儿童和青少年/年轻成人(AYA)患者的影响尚不清楚。这项回顾性病例系列研究旨在评估诊断性活检方法对黑色素瘤儿科/青壮年患者的分期、治疗和治疗相关结果的影响。在103名患有非典型皮肤黑色素细胞病变的儿科/青壮年患者中,最常见的活检方法是部分剃除(68/103,66.0%),其次是打孔(20/103,19.4%)、切除(14/103,13.6%)和切开非剃除(1/103,1%)。超过半数的活检结果为深部边缘阳性,反映出微观分期受到影响(56/103,55.4%),与其他技术相比,大部分活检结果为部分剃除(52/56,92.9%)(P < 0.001)。所有 11 例手术靶缘较宽的局部广泛切除患者和 8/9 例因深缘阳性而进行前哨淋巴结活检的患者都接受了部分剃除活检(P = 0.05 和 0.32,分别为 0.05 和 0.32)。在所有接受部分刮片活检的患者中,几乎有一半的患者在活检前曾有临床怀疑的异常黑色素细胞肿瘤(31/68,45.6%;P = 0.03)。在 56 位显微分期受损的患者中,17 位(30.4%)确诊为黑色素瘤(P = 0.17)。小儿/AYA 患者经常接受部分刮片活检,这与因微观分期受损而进行更具侵入性的明确手术治疗有关。这些结果可能有助于优化皮肤黑色素细胞肿瘤患者的治疗。
{"title":"Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients.","authors":"Akshaya Arjunan, Mary Wardrop, Marcus M Malek, Alexander J Davit, Michael R Sargen, John M Kirkwood, Kathryn Demanelis, Brittani K N Seynnaeve","doi":"10.1097/CMR.0000000000001002","DOIUrl":"10.1097/CMR.0000000000001002","url":null,"abstract":"<p><p>Pediatric melanoma is the most common skin cancer in children and treatment relies on accurate staging. The American Academy of Dermatology recommends excisional biopsy for suspicious skin lesions, however, partial shave biopsies are often performed, the impact of which is unknown in pediatric and adolescent/young adult (AYA) patients. The aim of this retrospective case series study was to evaluate the impact of the diagnostic biopsy method on staging, treatment, and treatment-related outcomes in pediatric/AYA patients with melanoma. Among 103 pediatric/AYA patients with atypical cutaneous melanocytic lesions, the most common biopsy method was partial shave (68/103, 66.0%) followed by punch (20/103, 19.4%), excisional (14/103, 13.6%), and incisional nonshave (1/103, 1%). Over half of all biopsies yielded a positive deep margin, reflecting compromised microstaging (56/103, 55.4%), the majority occurred following partial shave (52/56, 92.9%) compared with other techniques ( P  < 0.001). All 11 patients with wider surgical target margins of wide local excision and 8/9 patients with sentinel lymph node biopsy performed due to positive deep margin, underwent a partial shave biopsy ( P  = 0.05 and 0.32, respectively). Almost half of all patients who underwent partial shave biopsy had a clinically suspected abnormal melanocytic tumor prior to biopsy (31/68, 45.6%; P  = 0.03). Of 56 patients who had compromised microstaging, 17 (30.4%) had a diagnosis of melanoma ( P  = 0.17). Pediatric/AYA patients frequently undergo partial shave biopsy, which is associated with more invasive definitive surgical treatment due to compromised microstaging. These results may help optimize care of patients with cutaneous melanocytic tumors.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"544-548"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study. 儿科黑色素瘤预后提名图的开发与验证:一项基于人群的研究。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-30 DOI: 10.1097/CMR.0000000000000993
Saichun Zhang, Zixiang Liu, Dongsheng Zhu

The aim of the study is to use the Surveillance, Epidemiology, and End Results (SEER) database to develop a useful clinical nomogram that uses prognosis prediction for pediatric melanoma patients. We obtained clinical information on pediatric melanoma patients from the SEER database between 2000 and 2018. Each patient was split into a training cohort or a validation cohort at random. Results between various subgroups were compared using Kaplan-Meier analyses. We created a nomogram to calculate the probability of survival for pediatric patients with melanoma. The performance of nomograms was assessed using calibration and discrimination. To assess the clinical use of this newly created model, decision curve analysis was also performed. In this study, a total of 890 eligible patients were chosen at random and allocated to 70% of training cohorts ( n  = 623) and 30% of validation cohorts ( n  = 267). After applying the chosen various components to create a nomogram, validated indexes showed that the nomogram had a strong capacity for discrimination. The training set's and validation set's C-index values were 0.817 and 0.832, respectively. The calibration plots demonstrated a strong correlation between the observation and the forecast. The model has a good clinical net benefit for pediatric melanoma patients, according to the clinical decision curve. In conclusion, we created an effective survival prediction model for pediatric melanoma. This nomogram is accurate and useful for clinical decision-making. Still, more external confirmation is required.

本研究的目的是利用监测、流行病学和最终结果(SEER)数据库,为儿科黑色素瘤患者开发一个有用的临床预后预测提名图。我们从 SEER 数据库中获取了 2000 年至 2018 年间儿科黑色素瘤患者的临床信息。每位患者被随机分成训练组或验证组。我们使用卡普兰-梅耶分析比较了不同亚组之间的结果。我们创建了一个提名图来计算儿科黑色素瘤患者的生存概率。通过校准和辨别评估了提名图的性能。为了评估这个新创建模型的临床应用,我们还进行了决策曲线分析。在这项研究中,共随机选择了 890 名符合条件的患者,并将其分配到 70% 的训练队列(623 人)和 30% 的验证队列(267 人)中。在应用所选的各种成分创建提名图后,验证指标显示提名图具有很强的分辨能力。训练集和验证集的 C 指数值分别为 0.817 和 0.832。校准图显示观察结果与预测结果之间具有很强的相关性。根据临床决策曲线,该模型对小儿黑色素瘤患者具有良好的临床净效益。总之,我们创建了一个有效的小儿黑色素瘤生存预测模型。该提名图准确且有助于临床决策。但仍需要更多的外部证实。
{"title":"Development and validation of prognostic nomogram in pediatric melanoma: a population-based study.","authors":"Saichun Zhang, Zixiang Liu, Dongsheng Zhu","doi":"10.1097/CMR.0000000000000993","DOIUrl":"10.1097/CMR.0000000000000993","url":null,"abstract":"<p><p>The aim of the study is to use the Surveillance, Epidemiology, and End Results (SEER) database to develop a useful clinical nomogram that uses prognosis prediction for pediatric melanoma patients. We obtained clinical information on pediatric melanoma patients from the SEER database between 2000 and 2018. Each patient was split into a training cohort or a validation cohort at random. Results between various subgroups were compared using Kaplan-Meier analyses. We created a nomogram to calculate the probability of survival for pediatric patients with melanoma. The performance of nomograms was assessed using calibration and discrimination. To assess the clinical use of this newly created model, decision curve analysis was also performed. In this study, a total of 890 eligible patients were chosen at random and allocated to 70% of training cohorts ( n  = 623) and 30% of validation cohorts ( n  = 267). After applying the chosen various components to create a nomogram, validated indexes showed that the nomogram had a strong capacity for discrimination. The training set's and validation set's C-index values were 0.817 and 0.832, respectively. The calibration plots demonstrated a strong correlation between the observation and the forecast. The model has a good clinical net benefit for pediatric melanoma patients, according to the clinical decision curve. In conclusion, we created an effective survival prediction model for pediatric melanoma. This nomogram is accurate and useful for clinical decision-making. Still, more external confirmation is required.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"497-503"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma. 肛门直肠黑色素瘤:关于一种侵袭性黑色素瘤的现有文献的系统回顾。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-04 DOI: 10.1097/CMR.0000000000001003
Giovanni Paolino, Antonio Podo Brunetti, Carolina De Rosa, Carmen Cantisani, Franco Rongioletti, Andrea Carugno, Nicola Zerbinati, Mario Valenti, Domenico Mascagni, Giulio Tosti, Santo Raffaele Mercuri, Riccardo Pampena

Anorectal melanoma (ARM) is a rare malignancy often associated with a poor prognosis due to its late diagnosis and aggressive biological behavior. This review aims to comprehensively investigate ARM's diagnosis, management, and treatment, emphasizing its clinical characteristics, laboratory findings, and implications for patient prognosis. A systematic literature search was conducted in PubMed, Embase, and Cochrane CENTRAL databases from inception to 1 July 2024. This review synthesizes existing literature to provide a comprehensive understanding of this rare primary malignancy. A total of 110 articles reporting on 166 patients were included. Gender data were available for 131 cases, comprising 67 females (51.1%) and 64 males (48.9%). The median age was 66 years. The overall median time to diagnosis was 4 months for anal melanoma, 3 months for rectal melanoma, and 4 months for anorectal junction melanoma. The clinical presentation was nodular in 98.2% of cases. Pre-diagnosis symptoms included bleeding in 84.9% of cases, mucous elimination (6%), pain (68.7%), tenesmus (16.9%), and changes in bowel movements (28.5%). Overall survival (OS) was reported in 82 cases, with a median OS of 11 months: 11 months for anal melanoma, 7 months for rectal melanoma, and 12 months for anorectal junction melanoma. ARM is a rare and aggressive melanoma subtype often diagnosed at an advanced stage, leading to a poor prognosis. A female predominance was observed, consistent with other mucosal melanomas. Anal melanoma exhibited better progression-free survival, and OS compared to rectal and anorectal junction melanoma.

肛门直肠黑色素瘤(ARM)是一种罕见的恶性肿瘤,由于其诊断较晚且具有侵袭性生物学行为,通常预后较差。本综述旨在全面研究 ARM 的诊断、管理和治疗,强调其临床特征、实验室检查结果以及对患者预后的影响。我们在 PubMed、Embase 和 Cochrane CENTRAL 数据库中进行了系统性的文献检索,检索时间从开始到 2024 年 7 月 1 日。本综述综合了现有文献,以全面了解这种罕见的原发性恶性肿瘤。共收录了 110 篇文章,报告了 166 名患者的情况。131例病例有性别数据,其中女性67例(51.1%),男性64例(48.9%)。年龄中位数为 66 岁。肛门黑色素瘤确诊时间的中位数为4个月,直肠黑色素瘤为3个月,肛门直肠交界处黑色素瘤为4个月。98.2%的病例临床表现为结节状。诊断前症状包括出血(84.9%)、粘液排出(6%)、疼痛(68.7%)、痛经(16.9%)和排便改变(28.5%)。82例病例的总生存期(OS)中位数为11个月:肛门黑色素瘤的中位生存期为11个月,直肠黑色素瘤为7个月,肛门直肠交界处黑色素瘤为12个月。ARM是一种罕见的侵袭性黑色素瘤亚型,通常在晚期确诊,预后较差。据观察,女性患者居多,这与其他粘膜黑色素瘤的情况一致。与直肠黑色素瘤和肛门直肠交界处黑色素瘤相比,肛门黑色素瘤的无进展生存期和OS较好。
{"title":"Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma.","authors":"Giovanni Paolino, Antonio Podo Brunetti, Carolina De Rosa, Carmen Cantisani, Franco Rongioletti, Andrea Carugno, Nicola Zerbinati, Mario Valenti, Domenico Mascagni, Giulio Tosti, Santo Raffaele Mercuri, Riccardo Pampena","doi":"10.1097/CMR.0000000000001003","DOIUrl":"10.1097/CMR.0000000000001003","url":null,"abstract":"<p><p>Anorectal melanoma (ARM) is a rare malignancy often associated with a poor prognosis due to its late diagnosis and aggressive biological behavior. This review aims to comprehensively investigate ARM's diagnosis, management, and treatment, emphasizing its clinical characteristics, laboratory findings, and implications for patient prognosis. A systematic literature search was conducted in PubMed, Embase, and Cochrane CENTRAL databases from inception to 1 July 2024. This review synthesizes existing literature to provide a comprehensive understanding of this rare primary malignancy. A total of 110 articles reporting on 166 patients were included. Gender data were available for 131 cases, comprising 67 females (51.1%) and 64 males (48.9%). The median age was 66 years. The overall median time to diagnosis was 4 months for anal melanoma, 3 months for rectal melanoma, and 4 months for anorectal junction melanoma. The clinical presentation was nodular in 98.2% of cases. Pre-diagnosis symptoms included bleeding in 84.9% of cases, mucous elimination (6%), pain (68.7%), tenesmus (16.9%), and changes in bowel movements (28.5%). Overall survival (OS) was reported in 82 cases, with a median OS of 11 months: 11 months for anal melanoma, 7 months for rectal melanoma, and 12 months for anorectal junction melanoma. ARM is a rare and aggressive melanoma subtype often diagnosed at an advanced stage, leading to a poor prognosis. A female predominance was observed, consistent with other mucosal melanomas. Anal melanoma exhibited better progression-free survival, and OS compared to rectal and anorectal junction melanoma.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"487-496"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total body skin examination visits by dermatology providers in the 2011-2016 National Ambulatory Medical Care Survey. 2011-2016 年全国流动医疗护理调查中皮肤科医疗服务提供者的全身皮肤检查访问量。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-30 DOI: 10.1097/CMR.0000000000000995
Brandon Smith, Joe K Tung, Annie I Chen, Cassandra Mohr, Malgorzata K Nowakowska, Mackenzie R Wehner, Laura K Ferris
{"title":"Total body skin examination visits by dermatology providers in the 2011-2016 National Ambulatory Medical Care Survey.","authors":"Brandon Smith, Joe K Tung, Annie I Chen, Cassandra Mohr, Malgorzata K Nowakowska, Mackenzie R Wehner, Laura K Ferris","doi":"10.1097/CMR.0000000000000995","DOIUrl":"https://doi.org/10.1097/CMR.0000000000000995","url":null,"abstract":"","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"34 6","pages":"549-550"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study. 同步双原发性外阴黑色素瘤:一种并不罕见的可能性。临床和皮肤镜病例研究。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-24 DOI: 10.1097/CMR.0000000000000989
Vincenzo De Giorgi, Giovanni Cecchi, Gabriella Perillo, Biancamaria Zuccaro, Piero Covarelli

Vulvar melanoma is considered rare, but it is the second most frequent vulvar neoplasm; 2% of melanomas in women arise in the vulvar area. It is important to highlight how the characteristics of vulvar melanoma differentiate it from classic cutaneous melanoma. Vulvar melanoma has different risk factors and clinical and dermoscopic characteristics; moreover, it has a higher recurrence rate and a greater likelihood of multifocality. Here, we present a case of a 44-year-old patient with two primary vulvar melanomas located on opposite sides of her vulva. The lesions were both flat, but they had distinct clinical and dermoscopic appearances. Melanoma of the genital tract is likely the result of a multifocal disorder of the melanocytes within the mucosa that inhabit the perineal squamous epithelium. The risk factors of vulvar melanoma differ from those of classical cutaneous melanomas. Vulvar melanoma occurs in an area shielded from ultraviolet radiation; the primary risk factors include chronic inflammatory disease, genetic susceptibility, irritant agents and viral infections. This case study reveals how a close examination of the genital area is important and how dermoscopy can aid in the differential diagnosis of vulvar lesions. Inspections of the genital area should be particularly thorough if a melanoma is detected there, given the higher risk of multifocality in that part of the body.

外阴黑色素瘤被认为是罕见的,但它却是第二大最常见的外阴肿瘤;2%的女性黑色素瘤发生在外阴部位。强调外阴黑色素瘤的特征如何将其与典型的皮肤黑色素瘤区分开来非常重要。外阴黑色素瘤具有不同的风险因素、临床和皮肤镜特征;此外,它的复发率更高,而且更有可能发生多发性。在此,我们介绍一例 44 岁患者的病例,她患有两个原发性外阴黑色素瘤,分别位于外阴的两侧。病变都是扁平的,但它们的临床表现和皮肤镜表现截然不同。生殖道黑色素瘤很可能是会阴部鳞状上皮黏膜内黑色素细胞多灶性紊乱的结果。外阴黑色素瘤的危险因素与传统的皮肤黑色素瘤不同。外阴黑色素瘤发生在一个屏蔽紫外线辐射的区域;主要的危险因素包括慢性炎症、遗传易感性、刺激物和病毒感染。本病例研究揭示了仔细检查生殖器部位的重要性,以及皮肤镜如何帮助鉴别诊断外阴病变。如果在生殖器部位发现黑色素瘤,应特别彻底地检查该部位,因为该部位发生多发性黑色素瘤的风险较高。
{"title":"Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study.","authors":"Vincenzo De Giorgi, Giovanni Cecchi, Gabriella Perillo, Biancamaria Zuccaro, Piero Covarelli","doi":"10.1097/CMR.0000000000000989","DOIUrl":"10.1097/CMR.0000000000000989","url":null,"abstract":"<p><p>Vulvar melanoma is considered rare, but it is the second most frequent vulvar neoplasm; 2% of melanomas in women arise in the vulvar area. It is important to highlight how the characteristics of vulvar melanoma differentiate it from classic cutaneous melanoma. Vulvar melanoma has different risk factors and clinical and dermoscopic characteristics; moreover, it has a higher recurrence rate and a greater likelihood of multifocality. Here, we present a case of a 44-year-old patient with two primary vulvar melanomas located on opposite sides of her vulva. The lesions were both flat, but they had distinct clinical and dermoscopic appearances. Melanoma of the genital tract is likely the result of a multifocal disorder of the melanocytes within the mucosa that inhabit the perineal squamous epithelium. The risk factors of vulvar melanoma differ from those of classical cutaneous melanomas. Vulvar melanoma occurs in an area shielded from ultraviolet radiation; the primary risk factors include chronic inflammatory disease, genetic susceptibility, irritant agents and viral infections. This case study reveals how a close examination of the genital area is important and how dermoscopy can aid in the differential diagnosis of vulvar lesions. Inspections of the genital area should be particularly thorough if a melanoma is detected there, given the higher risk of multifocality in that part of the body.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"540-543"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea. 小儿黑色素瘤的发病率和存活率:韩国一项为期十五年的全国性回顾性队列研究(2004-2019 年)。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-30 DOI: 10.1097/CMR.0000000000001000
Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee

The aim of this study was to explore the epidemiology of cutaneous malignant melanoma (CMM) and the associated risk factors influencing its occurrence and survival among Koreans aged <20 years. In this retrospective cohort investigation, we identified cases of incident melanoma diagnosed in Korean patients aged 0-19 years between 2004 and 2019, utilizing the National Health Insurance database. We assessed annual fluctuations in age-adjusted incidence rates and examined 5-year survival rates based on various factors, including sex, age, income level, sun-exposed sites, and the Charlson Comorbidity Index. Of 1160 patients, 51.4% were male and 48.6% were female. The mean age of the patients was 11 years, mostly belonging to the top 25% high-income group. The head and neck regions were the most frequently affected sites. The overall age-adjusted incidence rate of melanoma was 0.22 per 100,000 persons. This rate witnessed a decline of 4.5% annually from 2004 to 2012, followed by a subsequent increase of 12.6% annually from 2012 to 2019. Notably, patients with CMM in low-sun-exposed sites exhibited poorer survival rates compared with those in high-sun-exposed areas ( P  < 0.05). The incidence of melanomas in children and adolescents in Korea has shown a rising trend since 2012. Further research is needed to investigate the etiology and risk factors in pediatric patients.

本研究的目的是探讨皮肤恶性黑色素瘤(CMM)的流行病学,以及影响其在韩国老年人中的发生率和存活率的相关风险因素。
{"title":"Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea.","authors":"Isaac Kim, Jisu Oh, Siyeoung Yoon, Man-Yong Han, Jaiwoo Chung, Younghoon Jung, Hyun-Il Lee, Soonchul Lee","doi":"10.1097/CMR.0000000000001000","DOIUrl":"10.1097/CMR.0000000000001000","url":null,"abstract":"<p><p>The aim of this study was to explore the epidemiology of cutaneous malignant melanoma (CMM) and the associated risk factors influencing its occurrence and survival among Koreans aged <20 years. In this retrospective cohort investigation, we identified cases of incident melanoma diagnosed in Korean patients aged 0-19 years between 2004 and 2019, utilizing the National Health Insurance database. We assessed annual fluctuations in age-adjusted incidence rates and examined 5-year survival rates based on various factors, including sex, age, income level, sun-exposed sites, and the Charlson Comorbidity Index. Of 1160 patients, 51.4% were male and 48.6% were female. The mean age of the patients was 11 years, mostly belonging to the top 25% high-income group. The head and neck regions were the most frequently affected sites. The overall age-adjusted incidence rate of melanoma was 0.22 per 100,000 persons. This rate witnessed a decline of 4.5% annually from 2004 to 2012, followed by a subsequent increase of 12.6% annually from 2012 to 2019. Notably, patients with CMM in low-sun-exposed sites exhibited poorer survival rates compared with those in high-sun-exposed areas ( P  < 0.05). The incidence of melanomas in children and adolescents in Korea has shown a rising trend since 2012. Further research is needed to investigate the etiology and risk factors in pediatric patients.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"528-534"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting. 在三甲医院接受治疗的老年黑色素瘤患者接受靶向治疗的疗效和毒性的真实证据。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-30 DOI: 10.1097/CMR.0000000000000997
Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane, Anastasios Dimou, Arkadiusz Z Dudek, Winston Tan, Roxana S Dronca, Mahesh Seetharam, Ruqin Chen, Matthew S Block

Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While most patients are treated with immunotherapy, the use of targeted therapy is a valid alternative for patients whose tumors harbor a BRAF or c-KIT driver mutation. These agents, while effective, come with a variety of side effects which limit their use, especially in older patients. We sought to assess the efficacy and toxicity of these agents in older melanoma patients. Melanoma patients over 65 treated with BRAF/MEK or c-KIT inhibitors were retrospectively identified, and their data were analyzed for treatment efficacy and toxicity. All data were compared using the Chi-square test for categorical comparisons and the Kruskal-Wallis method for median comparisons. One hundred and sixteen patients were identified. One hundred and six patients were treated with BRAF/MEK inhibitors. The assessed response rate (RR) was 83% and was comparable across different subgroups, including advanced line patients and those with a more aggressive disease. The median progression free survival (PFS) was 7.9 months, and the median overall survival (OS) was 15.7 months. Twenty-seven percent experienced grade 3-4 toxicity leading to a 24% treatment discontinuation rate. Another 10 patients were treated with the c-KIT inhibitor imatinib, for whom the assessed RR was 55%. The median PFS was 4.3 months, and the median OS was 22.6 months. Forty percent needed dose reductions, yet none had to stop treatment due to adverse effects. The use of targeted therapy in older patients is effective yet challenging due to toxicity. Deploying mitigation strategies can help maximizing their usefulness.

黑色素瘤是最致命的皮肤癌。确诊时的中位年龄为 66 岁。虽然大多数患者接受的是免疫疗法,但对于肿瘤携带 BRAF 或 c-KIT 驱动基因突变的患者来说,靶向疗法也是一种有效的替代疗法。这些药物虽然有效,但会产生各种副作用,限制了它们的使用,尤其是在老年患者中。我们试图评估这些药物对老年黑色素瘤患者的疗效和毒性。我们回顾性地确定了接受 BRAF/MEK 或 c-KIT 抑制剂治疗的 65 岁以上黑色素瘤患者,并分析了他们的疗效和毒性数据。所有数据的比较均采用Chi-square检验进行分类比较,采用Kruskal-Wallis方法进行中位数比较。最终确定了 116 名患者。116 名患者接受了 BRAF/MEK 抑制剂治疗。评估的应答率(RR)为83%,在不同亚组中具有可比性,包括晚期患者和病情更具侵袭性的患者。中位无进展生存期(PFS)为7.9个月,中位总生存期(OS)为15.7个月。27%的患者出现了3-4级毒性,导致24%的患者中断治疗。另有10名患者接受了c-KIT抑制剂伊马替尼治疗,评估的RR为55%。中位 PFS 为 4.3 个月,中位 OS 为 22.6 个月。40%的患者需要减少剂量,但没有人因不良反应而停止治疗。在老年患者中使用靶向疗法是有效的,但由于毒性的存在,也具有挑战性。采用缓解策略有助于最大限度地发挥其作用。
{"title":"Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.","authors":"Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane, Anastasios Dimou, Arkadiusz Z Dudek, Winston Tan, Roxana S Dronca, Mahesh Seetharam, Ruqin Chen, Matthew S Block","doi":"10.1097/CMR.0000000000000997","DOIUrl":"10.1097/CMR.0000000000000997","url":null,"abstract":"<p><p>Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While most patients are treated with immunotherapy, the use of targeted therapy is a valid alternative for patients whose tumors harbor a BRAF or c-KIT driver mutation. These agents, while effective, come with a variety of side effects which limit their use, especially in older patients. We sought to assess the efficacy and toxicity of these agents in older melanoma patients. Melanoma patients over 65 treated with BRAF/MEK or c-KIT inhibitors were retrospectively identified, and their data were analyzed for treatment efficacy and toxicity. All data were compared using the Chi-square test for categorical comparisons and the Kruskal-Wallis method for median comparisons. One hundred and sixteen patients were identified. One hundred and six patients were treated with BRAF/MEK inhibitors. The assessed response rate (RR) was 83% and was comparable across different subgroups, including advanced line patients and those with a more aggressive disease. The median progression free survival (PFS) was 7.9 months, and the median overall survival (OS) was 15.7 months. Twenty-seven percent experienced grade 3-4 toxicity leading to a 24% treatment discontinuation rate. Another 10 patients were treated with the c-KIT inhibitor imatinib, for whom the assessed RR was 55%. The median PFS was 4.3 months, and the median OS was 22.6 months. Forty percent needed dose reductions, yet none had to stop treatment due to adverse effects. The use of targeted therapy in older patients is effective yet challenging due to toxicity. Deploying mitigation strategies can help maximizing their usefulness.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"510-518"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142109348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience. 薄型黑色素瘤前哨淋巴结活检阴性患者的长期疗效和复发模式:单中心经验。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-14 DOI: 10.1097/CMR.0000000000000986
Maayan Shemer, Michal Shimonovitz, Rozalin Furer, Adam Abu-Abeid, Danit Dayan, Schlomo Schneebaum, Mor Miodovnik, Eran Nizri

The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm). Data on the rate and pattern of recurrence after a negative sentinel lymph node biopsy (SLNB) are sparse. We retrospectively searched our institutional database and retrieved the records of patients with thin melanomas who underwent an SLNB with negative results. We analyzed patterns of recurrence, time to recurrence, and mode of diagnosis. Thirteen of the 198 patients with thin melanomas and negative SLNB results had tumor recurrence (6.5%): two local in transit (15.4%), three regional (21.3%), and eight distant (61.5%). Distant recurrences tended to occur later than local or regional ones [median disease-free survival = 50 months (95% confidence interval: 36.1-63.9) vs. 34 and 15 months (95% confidence interval: 5.4-24.6), P  = 0.005, respectively]. The percentage of patients with tumor thickness ≥0.8 mm was higher among those who sustained recurrence (84.6 vs. 64.9% for no recurrence, P  = 0.04). The majority of patients with recurrence were not being followed up when diagnosed (69%), and they are presented because of clinical symptoms. Patients with recurrence had lower survival compared with those without recurrence (median: 118 months vs. ongoing survival, P  < 0.001, respectively). Melanoma recurrence in patients with thin melanomas and negative SLNBs is rare, tends to be distant, and negatively affects prognosis. Recurrence tends to occur in patients with melanoma thickness ≥0.8 mm. Further studies are needed to identify patients with high recurrence risk and determine optimal follow-up protocols.

大多数确诊的黑色素瘤患者的黑色素瘤较薄(≤1 毫米)。关于前哨淋巴结活检(SLNB)阴性后的复发率和复发模式的数据很少。我们回顾性地搜索了本机构的数据库,并检索了接受前哨淋巴结活检阴性结果的薄黑色素瘤患者的记录。我们分析了复发模式、复发时间和诊断方式。在198名SLNB结果为阴性的薄层黑色素瘤患者中,有13名患者(6.5%)出现了肿瘤复发:2名患者为局部中转复发(15.4%),3名患者为区域性复发(21.3%),8名患者为远处复发(61.5%)。远处复发往往晚于局部或区域性复发[中位无病生存期 = 50 个月(95% 置信区间:36.1-63.9) vs. 34 和 15 个月(95% 置信区间:5.4-24.6),P = 0.005]。复发患者中肿瘤厚度≥0.8毫米的比例更高(84.6%对64.9%,P = 0.04)。大多数复发患者在确诊时未接受随访(69%),他们因临床症状而就诊。与未复发的患者相比,复发患者的存活率较低(中位数:118 个月与持续存活时间相比,P = 0.05):118个月与持续生存期相比,P
{"title":"Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.","authors":"Maayan Shemer, Michal Shimonovitz, Rozalin Furer, Adam Abu-Abeid, Danit Dayan, Schlomo Schneebaum, Mor Miodovnik, Eran Nizri","doi":"10.1097/CMR.0000000000000986","DOIUrl":"10.1097/CMR.0000000000000986","url":null,"abstract":"<p><p>The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm). Data on the rate and pattern of recurrence after a negative sentinel lymph node biopsy (SLNB) are sparse. We retrospectively searched our institutional database and retrieved the records of patients with thin melanomas who underwent an SLNB with negative results. We analyzed patterns of recurrence, time to recurrence, and mode of diagnosis. Thirteen of the 198 patients with thin melanomas and negative SLNB results had tumor recurrence (6.5%): two local in transit (15.4%), three regional (21.3%), and eight distant (61.5%). Distant recurrences tended to occur later than local or regional ones [median disease-free survival = 50 months (95% confidence interval: 36.1-63.9) vs. 34 and 15 months (95% confidence interval: 5.4-24.6), P  = 0.005, respectively]. The percentage of patients with tumor thickness ≥0.8 mm was higher among those who sustained recurrence (84.6 vs. 64.9% for no recurrence, P  = 0.04). The majority of patients with recurrence were not being followed up when diagnosed (69%), and they are presented because of clinical symptoms. Patients with recurrence had lower survival compared with those without recurrence (median: 118 months vs. ongoing survival, P  < 0.001, respectively). Melanoma recurrence in patients with thin melanomas and negative SLNBs is rare, tends to be distant, and negatively affects prognosis. Recurrence tends to occur in patients with melanoma thickness ≥0.8 mm. Further studies are needed to identify patients with high recurrence risk and determine optimal follow-up protocols.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"535-539"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green. 利用吲哚菁绿的近红外荧光成像技术经皮检测皮肤黑色素瘤的前哨淋巴结。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-02 DOI: 10.1097/CMR.0000000000000994
Bo E Zweedijk, Antonius W Schurink, Thijs van Dalen, Tessa M van Ginhoven, Cornelis Verhoef, Bernd Kremer, Denise E Hilling, Stijn Keereweer, Dirk J Grünhagen

The aim of the study is to assess whether indocyanine green (ICG) fluorescence can replace technetium in the preoperative detection of sentinel lymph nodes (SLN) from cutaneous melanoma. The current golden standard for SLN detection is the radioisotope technetium. A promising alternative is fluorescence imaging (FLI) using ICG. In this study, we enrolled patients undergoing sentinel lymph node biopsy (SLNB) for skin melanoma at the Erasmus Medical Center between November 2022 and July 2023. The SLNB procedure was performed as a standard of care. After general anesthesia, ICG was injected intradermally around the primary tumor site. Both the patient and the surgeon were not blinded for the location of the SLN. FLI was performed before incision, in vivo after incision, and ex vivo. Fluorescent SLNs were confirmed using the gamma probe in all cases. Thirty-two patients were included in this study, and a total of 39 SLNs were harvested. The transcutaneous detection rate of ICG was 21.9%. The combined ex vivo ICG fluorescence and technetium uptake was 94.9%. One SLN contained only ICG (2.6%) and one SLN contained only technetium-uptake (2.6%). FLI using ICG resulted in a relatively low transcutaneous detection, which means that exclusive use of this technique in its present form is not feasible. However, we did find a high accumulation of ICG in the SLN, indicating the potential of ICG in combination with other imaging techniques.

这项研究旨在评估吲哚菁绿(ICG)荧光能否取代锝,用于术前检测皮肤黑色素瘤的前哨淋巴结(SLN)。目前,前哨淋巴结检测的黄金标准是放射性同位素锝。使用 ICG 进行荧光成像(FLI)是一种很有前途的替代方法。在这项研究中,我们招募了2022年11月至2023年7月期间在伊拉斯姆斯医学中心接受皮肤黑色素瘤前哨淋巴结活检(SLNB)的患者。前哨淋巴结活检手术按标准护理进行。全身麻醉后,在原发肿瘤周围皮内注射 ICG。患者和外科医生对 SLN 的位置均不设盲区。FLI 在切口前、切口后和体外进行。所有病例都使用伽马探针确认了荧光 SLN。本研究共纳入 32 名患者,共采集了 39 个 SLN。ICG 经皮检测率为 21.9%。体内ICG荧光和锝吸收率合计为94.9%。一个 SLN 仅含有 ICG(2.6%),一个 SLN 仅含有锝吸收(2.6%)。使用 ICG 进行 FLI 的经皮检测率相对较低,这意味着完全使用目前的这种技术是不可行的。不过,我们确实发现了 ICG 在 SLN 中的大量积聚,这表明 ICG 与其他成像技术结合使用的潜力。
{"title":"Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.","authors":"Bo E Zweedijk, Antonius W Schurink, Thijs van Dalen, Tessa M van Ginhoven, Cornelis Verhoef, Bernd Kremer, Denise E Hilling, Stijn Keereweer, Dirk J Grünhagen","doi":"10.1097/CMR.0000000000000994","DOIUrl":"10.1097/CMR.0000000000000994","url":null,"abstract":"<p><p>The aim of the study is to assess whether indocyanine green (ICG) fluorescence can replace technetium in the preoperative detection of sentinel lymph nodes (SLN) from cutaneous melanoma. The current golden standard for SLN detection is the radioisotope technetium. A promising alternative is fluorescence imaging (FLI) using ICG. In this study, we enrolled patients undergoing sentinel lymph node biopsy (SLNB) for skin melanoma at the Erasmus Medical Center between November 2022 and July 2023. The SLNB procedure was performed as a standard of care. After general anesthesia, ICG was injected intradermally around the primary tumor site. Both the patient and the surgeon were not blinded for the location of the SLN. FLI was performed before incision, in vivo after incision, and ex vivo. Fluorescent SLNs were confirmed using the gamma probe in all cases. Thirty-two patients were included in this study, and a total of 39 SLNs were harvested. The transcutaneous detection rate of ICG was 21.9%. The combined ex vivo ICG fluorescence and technetium uptake was 94.9%. One SLN contained only ICG (2.6%) and one SLN contained only technetium-uptake (2.6%). FLI using ICG resulted in a relatively low transcutaneous detection, which means that exclusive use of this technique in its present form is not feasible. However, we did find a high accumulation of ICG in the SLN, indicating the potential of ICG in combination with other imaging techniques.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"504-509"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141860205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Melanoma Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1